Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif®
Status:
Completed
Trial end date:
2018-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the proportion of patients who demonstrate no
medical need to discontinue therapy among DMT-naïve patients with relapsing forms of multiple
sclerosis after 1 year of treatment with Rebif 44 mcg tiw or with Tecfidera 240 mg bid based
on real-world data.